Ratings IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Market Closed - Nasdaq Stockholm Other stock markets 16:29:58 03/05/2024 BST			5-day change	1st Jan Change
10.95 ^SEK	-1.79%		+6.83%	+46.00%

03-22	IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	CI
03-19	IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
IRLAB THERAPEUTICS AB	+46.00%	52.58M	-
ELI LILLY AND COMPANY	+26.08%	662B	C+
NOVO NORDISK A/S	+21.85%	546B	B
JOHNSON & JOHNSON	-4.77%	359B	C+
MERCK & CO., INC.	+16.97%	323B	B-
ABBVIE INC.	+5.69%	290B	C+
ASTRAZENECA PLC	+13.68%	234B	B+
NOVARTIS AG	+3.65%	198B	B-
ROCHE HOLDING AG	-11.12%	194B	A+
AMGEN INC.	+8.08%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes